Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. - Test2 - elhamkhani - TriplyDB

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.

http://www.wikidata.org/entity/Q34638316

about

Advanced soft-tissue sarcoma and treatment options: critical appraisal of trabectedin New advances in targeted gastric cancer treatment A Systematic Literature Review of Adverse Events Associated with Systemic Treatments Used in Advanced Soft Tissue Sarcoma Trabectedin for Soft Tissue Sarcoma: Current Status and Future Perspectives Pazopanib in the management of advanced soft tissue sarcomas Targeting gastrointestinal stromal tumors: the role of regorafenib Targeting the Sonic Hedgehog Signaling Pathway: Review of Smoothened and GLI Inhibitors The value of trabectedin in the treatment of soft tissue sarcoma Targeting RTK Signaling Pathways in Cancer More than a Decade of Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors: What We Have Learned and What the Future Holds Epithelioid Sarcoma: Opportunities for Biology-Driven Targeted Therapy Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analyses Efficacy and safety of pharmacological interventions in second- or later-line treatment of patients with advanced soft tissue sarcoma: a systematic review Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: a systematic review and meta-analysis of clinical trials Children's Oncology Group's 2013 blueprint for research: Soft tissue sarcomas Pazopanib in sarcomas: expanding the PALETTE Risk of Infectious Complications in Hemato-Oncological Patients Treated with Kinase Inhibitors Potential for immunotherapy in soft tissue sarcoma Current and future options in the management and treatment of uterine sarcoma Risk of venous thromboembolic events associated with VEGFR-TKIs: a systematic review and meta-analysis TP53 mutational status is predictive of pazopanib response in advanced sarcomas.Practice guidelines for management of uterine corpus cancer in Korea: a Korean Society of Gynecologic Oncology Consensus Statement Advances in sarcoma diagnostics and treatment Update on clinical research and state of the art management of patients with advanced sarcomas and GIST Eribulin in the management of inoperable soft-tissue sarcoma: patient selection and survival Molecular Targets and Emerging Therapeutic Options for Uterine Leiomyosarcoma UK guidelines for the management of soft tissue sarcomas Efficacy and safety of eribulin mesylate in advanced soft tissue sarcomas Incidence and risk of hypertension associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a comprehensive network meta-analysis of 72 randomized controlled trials involving 30013 patients Microenvironmental Targets in Sarcoma Trabectedin in soft tissue sarcomas Enhancing Adolescent and Young Adult Oncology Research Within the National Clinical Trials Network: Rationale, Progress, and Emerging Strategies Management Strategies in Advanced Uterine Leiomyosarcoma: Focus on Trabectedin Treatment of Adult Soft Tissue Sarcomas: An Overview Pazopanib, a new therapy for metastatic soft tissue sarcoma Addition of Everolimus Post VEGFR Inhibition Treatment Failure in Advanced Sarcoma Patients Who Previously Benefited from VEGFR Inhibition: A Case Series The importance of treating by histological subtype in advanced soft tissue sarcoma.Advances and controversies in the management of soft tissue sarcomas.Treatment of soft tissue sarcoma: a focus on earlier stages.Platelet-derived growth factor receptor/platelet-derived growth factor (PDGFR/PDGF) system is a prognostic and treatment response biomarker with multifarious therapeutic targets in cancers.

P2860

Q26738346-AA693DC7-7F9E-42B6-B7B7-2D843584F133 Q26738548-74CEEA1B-BBEF-49C3-8326-F296D60B532B Q26741817-FD8BE56C-E8EA-49C2-9264-E92671C64122 Q26745502-72465B18-40CE-4E45-9A5F-D28F41FBC68D Q26746205-B0A65A8E-FAE3-44ED-86AE-EDEC2F52BD1C Q26747162-F029B19B-8D5C-4145-86F3-D92D13F0EE31 Q26764892-C2AD7B3F-659F-4E10-A078-DA8249CC68FF Q26772855-CB36C6E7-7CA6-4D2B-ADF4-6B6682C08E81 Q26781278-DDD6EF74-8609-468C-98C5-3A48F13F2800 Q26781662-F24895AA-6CC3-468B-8C44-0EF88300A7F8 Q26782730-EF7CD3DF-1251-4208-BC2D-D20A27C2E267 Q26786243-5248C7DD-ABA7-43AD-A47E-D678FE01A94C Q26822530-C13078E2-DBB9-4F02-BFFC-B174117C58EA Q26822790-C1EF347C-C317-460C-BFBE-E21D59C9A50C Q26825000-ED61A4EB-B839-4EB5-B72D-3E1DF03AAF9F Q26825050-DEA8795C-6225-4462-ACC4-0BE8F4C475CB Q26851417-E6A03DC5-D1B5-4A99-9831-F5A5E6912F38 Q27008830-2745DA61-895F-4553-B064-8200DB64579F Q27013559-137E3D6E-19C6-434C-B5C1-06200581C155 Q27026453-08710A60-143A-43D3-894D-59A54E080C78 Q27853289-6D525FF8-F548-4675-B2FF-EEDC114F4447 Q28069514-02E83312-F2D6-4220-BA75-87F9D140D68D Q28069695-53132A4F-7D85-4962-9D7B-DDF94785A152 Q28073290-48056CB2-B866-4A2C-ADE8-551A0847F131 Q28074125-D78215A1-1AAE-4812-9663-0F4BD82B211B Q28076023-39C4FAD2-3706-44E5-8BA6-4B5AF5B1CB3D Q28076730-DFB3FB79-52CB-4D09-A3A8-D12F89BFF087 Q28078116-1E51A102-BB61-4CEB-AA04-929128528D6D Q28079328-75D91E0C-BD4F-4249-95D0-4CF7EB72C59D Q28081400-949569A5-4ACC-40B7-954D-A9B6CCE53190 Q28085505-C059D3F8-5CF7-47A4-BB43-1F6E7CF37705 Q28086955-90FCCD04-0E4C-4CB3-8579-92D71AA02A31 Q28087771-C6CBCBCF-0344-4FEE-85D4-75335FFF05CA Q28088685-9AA13EB6-ED80-4788-8DDC-E3C8767522ED Q28287163-FAD0F848-CE1F-4DF4-8323-BA6E47A87762 Q28550228-624810C3-F409-4B10-BBEB-CEE3E1C7F659 Q30240223-50653A4C-8836-45FF-B598-4228F2E08CF0 Q30240228-692B62E6-ED12-4329-A4D5-C8CE4FD7F9C8 Q30240235-C34ECB77-91DF-40EE-B4C4-F1D46AC7DA30 Q30250273-8A6AAF31-639C-4B4E-8C87-1AF2B986D46C

P2860

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.

http://www.wikidata.org/entity/Q34638316

description

2012 nî lūn-bûn

@nan

2012 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Pazopanib for metastatic soft- ...... cebo-controlled phase 3 trial.

@ast

Pazopanib for metastatic soft- ...... cebo-controlled phase 3 trial.

@en

Pazopanib for metastatic soft- ...... cebo-controlled phase 3 trial.

@nl

type

label

Pazopanib for metastatic soft- ...... cebo-controlled phase 3 trial.

@ast

Pazopanib for metastatic soft- ...... cebo-controlled phase 3 trial.

@en

Pazopanib for metastatic soft- ...... cebo-controlled phase 3 trial.

@nl

prefLabel

Pazopanib for metastatic soft- ...... cebo-controlled phase 3 trial.

@ast

Pazopanib for metastatic soft- ...... cebo-controlled phase 3 trial.

@en

Pazopanib for metastatic soft- ...... cebo-controlled phase 3 trial.

@nl

P1433

Q34638316-852A7062-24A0-4182-B73F-2CBDCDD7A0EE

P1476

Q34638316-C5FB3D9D-B182-4BC1-9E1A-6116C96116A2

P2093

Q34638316-064423D8-D7F7-493C-8B74-B6F9A64C9277

Q34638316-0778CA0D-023C-43F4-8F19-BE3FA37A7750

Q34638316-0B5B9B0E-EF99-4B7B-A6E1-6A9D8E60BC6F

Q34638316-223D1C64-2685-4A78-97DD-A8CCE80A0125

Q34638316-250B5144-F0EB-49F6-9C5E-B40A3C4AA431

Q34638316-30CB7849-634B-46AF-B795-06FFE04EB98C

Q34638316-3F018C2C-225D-4587-A1A0-6285874A98FD

Q34638316-403B011D-057E-4094-A569-46D1ADD56B5E

Q34638316-43F7338B-E3B8-44F4-9169-9A2A75053917

Q34638316-479C852A-CA6F-45F0-A654-12A3AA616B9C

P304

Q34638316-38512F9E-4E76-4CE7-9C1B-9A0D14F7B089

P31

Q34638316-EFF0F090-8D4C-4B83-960C-3FE660A28DD8

P356

Q34638316-23CE3297-08EE-40FC-B3FB-091450FD16FB

P407

Q34638316-1B9E9848-84E1-49F2-A631-B8C503D25CD1

P433

Q34638316-CD98E44D-3A2E-47F1-BBC7-1204612D1E36

P478

Q34638316-8BB00C13-2001-416A-940E-9027B8A72E83

P50

Q34638316-5076964E-9147-4E9F-8B2F-A9F1059A969C

Q34638316-61A3FCE7-7F2E-443D-B019-A2648CBBC671

Q34638316-72C4E967-FE8B-4D83-97B2-EA74D9F324F0

Q34638316-9E2AFEEC-62C1-4487-8A91-6754A727C1E4

Q34638316-ADDE5C03-D8FB-4A94-B44C-58A63519189A

P577

Q34638316-2A8D7703-07FB-4086-83D0-27E5B29A8B94

P698

Q34638316-D37EB34B-C0EA-402E-9254-88D2B7B8D484

P921

Q34638316-10EBCD88-2844-407B-B026-05399F56160F

Q34638316-1D52AE02-4D32-4CE6-8358-305002FF31AC

Q34638316-50C4F4FF-D6A1-4843-86A1-882A55E37385

P356

S0140-6736(12)60651-5

P1433

P1476

Pazopanib for metastatic soft- ...... cebo-controlled phase 3 trial.

@en

P2093

Arthur P Staddon

http://www.w3.org/2001/XMLSchema#string

Binh Bui-Nguyen

http://www.w3.org/2001/XMLSchema#string

Christopher D Fletcher

http://www.w3.org/2001/XMLSchema#string

Corneel Coens

http://www.w3.org/2001/XMLSchema#string

Dong-Wan Kim

http://www.w3.org/2001/XMLSchema#string

EORTC Soft Tissue and Bone Sarcoma Group

http://www.w3.org/2001/XMLSchema#string

George D Demetri

http://www.w3.org/2001/XMLSchema#string

Hans Gelderblom

http://www.w3.org/2001/XMLSchema#string

Ian R Judson

http://www.w3.org/2001/XMLSchema#string

Massimo Aglietta

http://www.w3.org/2001/XMLSchema#string

P304

1879-1886

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S0140-6736(12)60651-5

http://www.w3.org/2001/XMLSchema#string

P407

P433

9829

http://www.w3.org/2001/XMLSchema#string

P478

379

http://www.w3.org/2001/XMLSchema#string

P50

Patrick Schöffski

Paolo Giovanni Casali

Angelo Paolo Dei Tos

P577

2012-05-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22595799

http://www.w3.org/2001/XMLSchema#string

P921

phase III clinical trial